Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 1, 2005, Pages 382-390

  May, Lauren T ^a   Lin, Yvonne ^a   Sexton, Patrick M ^a   Christopoulos, Arthur ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALCURONIUM; ATROPINE; CARBACHOL; GALLAMINE; HEPTANE 1,7 BIS(DIMETHYL 3' PHTHALIMIDOPROPYL) AMMONIUM BROMIDE; METHYLSCOPOLAMINE; MUSCARINIC M2 RECEPTOR; NEUROMUSCULAR BLOCKING AGENT; UNCLASSIFIED DRUG; GALLAMINE TRIETHIODIDE; HEPTANE 1,7 BIS (DIMETHYL 3' PHTHALIMIDOPROPYL)AMMONIUM BROMIDE; HEPTANE-1,7-BIS-(DIMETHYL-3'-PHTHALIMIDOPROPYL)AMMONIUM BROMIDE; LIGAND; NICOTINIC RECEPTOR BLOCKING AGENT; PHTHALIMIDE DERIVATIVE; QUATERNARY AMMONIUM DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING ASSAY; CELL METABOLISM; CELL TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; INTERNALIZATION; LIGAND BINDING; NONHUMAN; OVARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ALLOSTERISM; ANIMAL; CHO CELL; FEMALE; GENE EXPRESSION; HAMSTER; METABOLISM; TIME;

ALCURONIUM; ALLOSTERIC REGULATION; ANIMALS; CHO CELLS; CRICETINAE; FEMALE; GALLAMINE TRIETHIODIDE; GENE EXPRESSION; LIGANDS; NICOTINIC ANTAGONISTS; PHTHALIMIDES; QUATERNARY AMMONIUM COMPOUNDS; RECEPTOR, MUSCARINIC M2; TIME FACTORS;

EID: 11844253226     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.073767     Document Type: Article

References (36)

1. Avlani VA, May LT, Sexton PM, and Christopoulos A (2004) Application of a kinetic model to the apparently complex behaviors of negative and positive allosteric modulators of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 308: 1062-1072.
2. 1 adenosine receptors. Mol Pharmacol 50:104-111.
3. Birdsall NJ, Lazareno S, and Matsui H (1996) Allosteric regulation of muscarinic receptors. Prog Brain Res 109:147-151.
4. Bunemann M, Lee KB, Pals-Rylaarsdam R, Roseberry AG, and Hosey MM (1999) Desensitization of G-protein-coupled receptors in the cardiovascular system. Annu Rev Physiol 61:169-192.
5. Christopoulos A (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol Sci 19:351-357.
6. Christopoulos A (2000) Quantification of allosteric interactions at G protein-coupled receptors using radioligand binding assays, in Current Protocols in Pharmacology (Enna SJ ed) pp 1.22.21-21.22.40, John Wiley & Sons, NY.
7. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1:198-210.
8. Christopoulos A, Grant MK, Ayoubzadeh N, Kim ON, Sauerberg P, Jeppesen L, and El-Fakahany EE (2001) Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther 298:1260-1268.
9. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
10. Christopoulos A, Lanzafame A, and Mitchelson F (1998) Allosteric interactions at muscarinic cholinoceptors. Clin Exp Pharmacol Physiol 25:184-194.
11. Drews J (2000) Drug discovery: a historical perspective. Science (Wash DC) 287: 1960-1964.
12. Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187-194.
13. Ellis J (1997) Allosteric binding sites on muscarinic receptors. Drug Dev Res 40:193-204.
14. Ellis J and Seidenberg M (1992) Two allosteric modulators interact at a common site on cardiac muscarinic receptors. Mol Pharmacol 42:638-641.
15. Gether U, Ballesteros JA, Seifer R, Sanders-Bush E, Weinstein H, and Kobilka BK (1997) Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 272:2587-2590.
16. Holzgrabe U and Mohr K (1998) Allosteric modulators of ligand binding to muscarinic acetylcholine receptors. Drug Disc Today 3:214-222.
17. 4 subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists. FEBS Lett 377:275-279.
18. Jakubík J, Bacakova L, Lisa V, El-Fakahany EE, and Tucek S (1996) Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc Natl Acad Sci USA 93:8705-8709.
19. o protein stoichiometry. Mol Pharmacol 54:899-906.
20. Kenakin T (2002) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349-379.
21. Koenig JA and Edwardson JM (1996) Intracellular trafficking of the muscarinic acetylcholine receptor: importance of subtype and cell type. Mol Pharmacol 49: 351-359.
22. 2 receptors. J Pharmacol Exp Ther 282:278-285.
23. Lazareno S and Birdsall NJM (1995) Detection, quantitation and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
24. Lazareno S and Birdsall NJM (1999) Measurement of competitive and allosteric interactions in radioligand binding studies, in G Protein-Coupled Receptors (Haga T and Berstein G eds) pp 1-48, CRC Press, Boca Raton, FL.
25. 4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol 65:257-266.
26. Lee NH and El-Fakahany EE (1991) Allosteric antagonists of the muscarinic acetylcholine receptor. Biochem Pharmacol 42:199-205.
27. May LT and Christopoulos A (2003) Allosteric modulators of G-protein-coupled receptors. Curr Opin Pharmacol 3:551-556.
28. Milligan G and Bond RA (1997) Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18:468-474.
29. Motulsky HJ and Christopoulos A (2004) Fitting Models to Biological Data Using Linear and Nonlinear Regression. A Practical Guide to Curve Fitting. Oxford University Press, New York.
30. Neubig RR, Spedding M, Kenakin T, and Christopoulos A (2003) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55:597-606.
31. Pals-Rylaarsdam R, Gurevich W, Lee KB, Ptasienski JA, Benovic JL, and Hosey MM (1997) Internalization of the m2 muscarinic acetylcholine receptor. Arrestin-independent and -dependent pathways. J Biol Chem 272:23682-23689.
32. Pitcher JA, Freedman NJ, and Lefkowitz RJ (1998) G protein-coupled receptor kinases. Annu Rev Biochem 67:653-692.
33. 2 receptors. Mol Pharmacol 54:139-145.
34. Tsuga H, Kameyama K, and Haga T (1998) Desensitization of human muscarinic acetylcholiue receptor m2 subtypes is caused by their sequestration/internalization. J Biochem 124:863-868.
35. Tucek S and Proska J (1995) Allosteric modulation of muscarinic acetylcholine receptors. Trends Pharmacol Sci 16:205-212.
36. Zahn K, Eckstein N, Trankle C, Sadee W, and Mohr K (2002) Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. J Pharmacol Exp Ther 301:720-728.